WORKING TOGETHER TO FIGHT COVID-19



America's biopharmaceutical companies have joined forces to fight COVID-19.

Armed with experience garnered from previous outbreaks and a vast storehouse of knowledge about infectious diseases like influenza, malaria and HIV, researchers are working to develop and deliver diagnostics, treatments and vaccines to save lives and restore the rhythms of daily life for billions of people.

DIAGNOSTICS

It's essential to know who has been infected.

Companies are accelerating the development of diagnostic testing capabilities to scale-up screening and working in partnership with governments and diagnostic companies on existing screening programs to supplement testing.

EXISTING MEDICINES

Medicines approved for other diseases may have some benefit for patients with COVID-19.

- Researchers are testing antivirals, antibiotics and other medicines.
- These medicines have the potential to reduce the burden of COVID-19 on hospitals by reducing the length and severity of disease.

NEW TREATMENTS

Various drugs are in development, with some entering human trials.

- Researchers are working on new antiviral medications to interfere with ways the virus infects cells and reproduces.
- Antibody-based drugs may be able to mobilize the immune system against the virus.

VACCINES

A vaccine would provide a preventive approach to beating COVID-19.

Although vaccines can take longer to develop than other treatments, once enough people in a community are vaccinated, individuals are protected and the community risk of transmission is reduced. A variety of biopharmaceutical companies are taking different approaches to find a vaccine. More "shots on goal" will significantly increase the chances of success.

MANUFACTURING

We are committed to manufacturing these medicines and making them available to those who need them.

 We're ramping up output of existing medicines with demonstrated benefit and investing in infrastructure to accelerate production of new treatments.

Biopharmaceutical companies are planning and building manufacturing capacity without assurance medicine and vaccine candidates will ultimately be successful, to ensure that if one is, distribution can occur rapidly.

America's biopharmaceutical companies are ensuring that solutions can be made available quickly to everyone who needs them.